サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514157

RNA干渉（RNAi）の世界市場

RNA Interference (RNAi)

出版日
ページ情報
英文 178 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
RNA干渉（RNAi）の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 178 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

RNA干渉（RNAi）の世界市場は2030年までに2,067億米ドルに達する見込み

2023年に994億米ドルと推定されるRNA干渉（RNAi）の世界市場は、分析期間2023-2030年にCAGR 11.0%で成長し、2030年には2,067億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである創薬・開発アプリケーションは、CAGR 16.4%を記録し、分析期間終了時には1,181億米ドルに達すると予測されます。治療薬アプリケーション分野の成長率は、分析期間中CAGR 5.7%と推定されます。

米国市場は256億米ドルと推定、中国はCAGR17.3％で成長予測

米国のRNA干渉（RNAi）市場は、2023年に256億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに595億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは17.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と8.4%と予測されています。欧州では、ドイツがCAGR約6.4%で成長すると予測されています。

世界のRNA干渉（RNAi）市場動向と促進要因まとめ

RNA干渉（RNAi）は、RNA分子が遺伝子発現を阻害する重要な生物学的プロセスであり、標的となるメッセンジャーRNA（mRNA）分子を中和することで遺伝子をサイレンシングする役割から発見されたメカニズムです。遺伝子のコード化、解読、制御、発現に不可欠なRNAは、それぞれ約22ヌクレオチド長の低分子干渉RNA（siRNA）とマイクロRNA（miRNA）という2種類の低分子RNA分子によってRNAiを促進します。siRNAは、特定のmRNAを特異的に標的にして沈黙させ、タンパク質の産生を阻止するように設計されており、二本鎖RNAから加工され、切断されて細胞質に輸送されます。逆にmiRNAは、ヘアピン構造に折りたたまれた一本鎖RNAから作られ、広くタンパク質合成を制御します。アンドリュー・ファイヤーとクレイグ・メロに2006年のノーベル賞をもたらしたこの発見は、RNAiがゲノム寄生虫に対する自然な防御であり、タンパク質合成における重要な調節因子であることを明確にしました。

RNAiメカニズムは、siRNAとmiRNAがRNA誘導サイレンシング複合体（RISC）を標的mRNAに誘導し、mRNAの翻訳を阻害し、分解をシグナルするという複雑な経路で作動します。このプロセスは、mRNAがタンパク質合成に必要な寿命を超えないようにするために極めて重要です。RNAiの治療的意義は大きく、分子生物学において遺伝子発現を微調整する精密なツールを提供し、遺伝子機能の研究や創薬標的の検証に役立てることができます。この方法は、ゲノムを変化させることなくタンパク質の発現を減らして機能を調べる「ノックダウン」実験において特に有用です。特定の遺伝子を選択的に阻害するRNAiの能力は、病気を管理するための強力な候補となり、機能不全に陥ったタンパク質を標的とすることで、従来は既存の治療法では困難であった病態に新たな治療手段を提供します。

RNAi技術は、脂質ナノ粒子を用いたRNAiデリバリー機構の改良、安定したRNAi化合物の開発、遺伝子ターゲティングの精度向上などの進歩に後押しされ、医療と農業の両分野で成長の原動力となっています。CRISPRのような他のゲノムツールとの統合は、ゲノム研究における有用性を高める。さらに、RNAiの特異性によって個々の遺伝子プロファイルに合わせた治療が可能となる個別化医療への需要の高まりは、カスタム治療戦略におけるRNAiの可能性を浮き彫りにしています。農業分野では、収穫量の増加、害虫抵抗性、栄養プロファイルの改善を伴う作物の開発におけるRNAiの応用が、持続可能な実践への貢献を実証しています。RNAiベースの治療薬に対する規制当局の承認と、官民双方からの多額の資金提供により、RNAi技術の採用と開発が加速しており、遺伝子治療、医薬品開発、環境持続可能性における大きな進歩が期待されています。

調査対象企業の例（注目の12社）

  • Alnylam Pharmaceuticals, Inc.
  • Benitec BioPharma
  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Qiagen, Inc.
  • Quark Pharmaceuticals, Inc.
  • Silence Therapeutics PLC

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6819

Global RNA Interference (RNAi) Market to Reach US$206.7 Billion by 2030

The global market for RNA Interference (RNAi) estimated at US$99.4 Billion in the year 2023, is expected to reach US$206.7 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2023-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 16.4% CAGR and reach US$118.1 Billion by the end of the analysis period. Growth in the Therapeutics Application segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.6 Billion While China is Forecast to Grow at 17.3% CAGR

The RNA Interference (RNAi) market in the U.S. is estimated at US$25.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$59.5 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global RNA Interference (RNAi) Market - Key Trends and Drivers Summarized

RNA interference (RNAi) is a vital biological process where RNA molecules inhibit gene expression, a mechanism discovered due to its role in silencing genes by neutralizing targeted messenger RNA (mRNA) molecules. RNA, essential in the coding, decoding, regulation, and expression of genes, facilitates RNAi through two types of small RNA molecules: small interfering RNA (siRNA) and microRNA (miRNA), each about 22 nucleotides long. SiRNAs are engineered to specifically target and silence particular mRNAs, preventing protein production, and are processed from double-stranded RNA, which is cleaved and transported into the cytoplasm. Conversely, miRNAs, originating from single-stranded RNA that folds into hairpin structures, broadly regulate protein synthesis. This discovery, which brought Andrew Fire and Craig Mello the Nobel Prize in 2006, underscored RNAi as a natural defense against genomic parasites and a crucial regulator in protein synthesis.

The RNAi mechanism operates through a complex pathway where siRNAs and miRNAs guide the RNA-induced silencing complex (RISC) to target mRNAs, blocking their translation and signaling their degradation. This process is pivotal for ensuring that mRNAs do not exceed their necessary lifespan in protein synthesis. The therapeutic implications of RNAi are significant, providing a precise tool in molecular biology to fine-tune gene expression for studying gene functions and validating drug targets. This method is particularly valuable in "knockdown" experiments, where protein expression is reduced to investigate function without altering the genome. RNAi's ability to selectively inhibit specific genes makes it a powerful candidate for managing diseases, offering new treatment avenues for conditions traditionally challenging with existing therapies by targeting malfunctioning proteins.

RNAi technology is a growth driver in both medical and agricultural fields, propelled by advancements such as improved RNAi delivery mechanisms using lipid nanoparticles, development of stable RNAi compounds, and enhanced precision in gene targeting. Its integration with other genomic tools like CRISPR enhances its utility in genomic research. Additionally, the rising demand for personalized medicine, where RNAi's specificity can tailor treatments to individual genetic profiles, highlights its potential in custom therapeutic strategies. In agriculture, RNAi's application in developing crops with increased yield, pest resistance, and improved nutritional profiles demonstrates its contribution to sustainable practices. Regulatory approvals for RNAi-based therapeutics and substantial funding from both public and private sectors are accelerating the adoption and development of RNAi technologies, promising significant advancements in gene therapy, drug development, and environmental sustainability.

Select Competitors (Total 12 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • Benitec BioPharma
  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Qiagen, Inc.
  • Quark Pharmaceuticals, Inc.
  • Silence Therapeutics PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • RNA Interference (RNAi) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in RNAi Delivery Technologies Expand Addressable Market Opportunity
    • Increasing Investment in RNAi Research and Development Propels Growth
    • Successful Clinical Trials Throws the Spotlight on RNAi Therapeutics
    • Rising Prevalence of Chronic Diseases Drives Adoption of RNAi Solutions
    • Innovations in Nanoparticle Delivery Systems Spur Market Adoption
    • Integration with CRISPR and Gene Editing Technologies Generates Demand
    • Expanding Applications in Oncology and Rare Diseases Sustain Growth
    • Advancements in Bioinformatics and Computational Biology Drive RNAi Research
    • Emergence of RNAi-based Therapeutics for Infectious Diseases Expands Market Opportunities
    • Rising Focus on Personalized Medicine Propels Growth in RNAi Applications
    • Challenges in Off-Target Effects and Safety Impact Adoption
    • Technological Innovations in siRNA and shRNA Constructs Drive Market Adoption
    • Integration with Drug Delivery Platforms Strengthens RNAi Efficacy
    • Cost Reductions in RNA Synthesis and Manufacturing Spur Market Growth
    • Technological Convergence with Other Therapeutic Modalities Expands Market Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for RNA Interference (RNAi) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Ocular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Ocular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Ocular Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Respiratory Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Neuronal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Neuronal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Neuronal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World RNA Interference (RNAi) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • JAPAN
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • CHINA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • EUROPE
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for RNA Interference (RNAi) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • FRANCE
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • GERMANY
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for RNA Interference (RNAi) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • INDIA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for RNA Interference (RNAi) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for RNA Interference (RNAi) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • AFRICA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030

IV. COMPETITION